Medicine

The case for biosimilars

An organized group of pills
Photo: Dwight Eschliman/Getty Images

It's too soon to throw in the towel on biosimilars, especially because there's evidence that they're lowering the net costs of biologics, Alex Brill and Benedic Ippolito of the American Enterprise Institute argue in a Health Affairs blog.

Why it matters: The authors were refuting an April post in Health Affairs that argued biologics are a natural monopoly, so biosimilars aren't going to work.

Specialty drugs' steep price hikes

Adapted from AARP; Chart: Axios Visuals

The cost of specialty drugs has skyrocketed over the last decade, with the cost of 61 widely used drugs almost tripling between 2006 and 2017, according to a new AARP report.

By the numbers: The average annual cost of a specialty drug in 2017 was almost $20,000 more than the median U.S. household income.